Taxanes in the treatment of breast cancer: A prodigy comes of age

Cancer Investigation

Volumn 17, Issue 2, 1999, Pages 121-136

  Miller, Kathy D ^a,b   Sledge Jr , George W ^a  

^a INDIANA UNIVERSITY   (United States)

^b Indiana Cancer Pavilion   (United States)

Author keywords

Breast cancer; Chemotherapy; Docetaxel; Paclitaxel

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOCETAXEL; DOXORUBICIN; PACLITAXEL; TAXANE DERIVATIVE;

BREAST CANCER; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0032968717     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1080/07357909909011727     Document Type: Review

References (156)

1. Landis S, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 48:6-29, 1998.
2. Harris J, Lippman M, Veronesi U, et al: Breast cancer (third of three parts). N Engl J Med 327:473-480, 1992.
3. Parker S, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 47:5-27, 1997.
4. Leonard R, Rodger A, Dixon J: ABC of breast diseases. Metastatic breast cancer. BMJ 309:1501-1504, 1994.
5. Rowinsky E, Donehower R: Paclitaxel (Taxol). N Engl J Med 332:1004-1014, 1995.
6. Cortes J, Pazdur R: Docetaxel. J Clin Oncol 13:2643-2655, 1995.
7. Schiff P, Fant J, Horowitz S: Promotion of microtubule assembly in vitro by taxol. Nature 227:665-667, 1979.
8. Diaz J, Andreu J: Assembly of purified GDP-tubulin into microtubules induced by RP56976 and paclitaxel: reversibility, ligand stoichiometry and competition. Biochemistry 32:2747-2755, 1993.
9. Fromes Y, Gounan P, Bissery M-C, et al: Differential effects of taxol or taxotere on tau or MAP2 containing microtubules. Proc Am Assoc Cancer Res 33:551, 1992.
10. Tischler R, Schiff P, Geard C, et al: Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22:613-617, 1992.
11. Choy H, Rodriguez F, Wilcox B, et al: Radiation sensitizing effects of taxotere (RP56976). Proc Am Assoc Cancer Res 33:550, 1992.
12. Burkhart C, Berman J, Swindell C, et al: Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor gene expression and cytotoxicity. Cancer Res 54:5779-5782, 1994.
13. Belotti D, Nicoletti I, Vergani V, et al: Paclitaxel (Taxol), a microtubule affecting drug, inhibits tumor angiogenesis. Proc Am Assoc Cancer Res 37:57, 1996.
14. Lau D, Young L, Xue L, et al: Paclitaxel: an angiogenesis antagonist in a metastatic breast cancer model. Proc Am Soc Clin Oncol 17:107, 1998.
15. Zon R, Neuberg D, Wood W, et al: Correlation of plasma VEGF with clinical outcome in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 17:185, 1998.
16. Liebman J, Cook J, Lipschultz C, et al: Cytotoxic studies of paclitaxel (taxol) in human tumor cell lines. Br J Cancer 68:1104-1109, 1993.
17. Bissery M-C, Guenard D, Gueritte-Voegelein F, et al: Experimental antitumor activity of taxotere (RP56976, NSC628503), a taxol analogue. Cancer Res 51:4845-4852, 1991.
18. Riou J, Petitgenet O, Combeau C, et al: Cellular uptake and efflux of docetaxel (taxotere) and paclitaxel (taxol) in P388 cell line. Proc Am Assoc Cancer Res 35:385, 1994.
19. Cabral F, Wible L, Brenner S, et al: Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol 97:22-29, 1983.
20. Horowitz S, Cohen D, Rao S, et al: Taxol: mechanisms of action and resistance. Monogr Natl Cancer Inst 15:55-61, 1993.
21. Peereboom D, Donehower R, Eisenhauer E, et al: Successful retreatment with taxol after major hypersensitivity reactions. J Clin Oncol 11:885-890, 1993.
22. Wanders J, van Oosterom A, Gore M, et al: Taxotere toxicity-protective effects of premedication. Eur J Cancer 29A:S206, 1993.
23. Wanders J, Schrijvers D, Bruntsch U, et al: The EORTC-ECTG experience with acute hypersensitivity reactions in taxotere studies. Proc Am Soc Clin Oncol 12:73, 1993.
24. Holmes F, Valero V, Walters R, et al: Phase III trial of paclitaxel (P) administered over 3- or 96-hr for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 15:106, 1996.
25. Stein M, Drumea K, Abu-Rasmi R, et al: Taxol-induced cellulitis after extravasation: a rarely reported event. Am J Clin Oncol 20:540, 1997.
26. Pestalozzi B, Sotos G, Choyke P, et al: Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer. Cancer 17:1797-1800, 1992.
27. Oulid-Aissa D, Behar A, Spielmann M, et al: Management of fluid retention syndrome in patients treated with taxotere: effect of premedication. Proc Am Soc Clin Oncol 13:465, 1994.
28. Ravdin P, Valero V, Nabholtz J-M, et al: Efficacy of a 5-day corticosteroid premedication in ameliorating taxotere induced fluid retention. Proc Am Soc Clin Oncol 15:115, 1996.
29. Schrijvers D, Wanders J, Dirix L, et al: Coping with toxicities of docetaxel (taxotere). Ann Oncol 4:610-611, 1993.
30. Piccart M, Klijn J, Paridaems R, et al: Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch. J Clin Oncol 15:3149-3155, 1997.
31. Zimmerman G, Keeling J, Barris H, et al: Acute cutaneous reactions to docetaxel. Arch Dematol 131:202-206, 1995.
32. Llombart-Cussac A, Pivot X, Spielmann M: Docetaxel chemotherapy induces transverse superficial loss of the nail plate. Arch Dermatol 133:1466-1467, 1997.
33. Holmes F, Walters R, Theriault R, et al: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991.
34. Reichman B, Seidman A, Crown J, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993.
35. Seidman A, Tiersten A, Hudis C, et al: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13:2575-2581, 1995.
36. Mamounas E, Brown A, Fisher B, et al: 3-Hour high-dose taxol infusion in advanced breast cancer. An NSABP phase II study. Proc Am Soc Clin Oncol 14:127, 1995.
37. Swain S, Honig S, Walton L: Phase II trial of paclitaxel (taxol) as first line chemothrapy for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 14:132, 1995.
38. Seidman A, Reichman B, Crown J, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995.
39. Uziely B, Delaflor-Weiss E, Lenz H, et al: Paclitaxel (taxol) in refractory breast cancer: response correlates with low levels of MDR1 gene expression. Proc Am Soc Clin Oncol 13-75 1994
40. Nabholtz J-M, Gelmon K, Bontenbal M, et al: Multicenter randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867 1996
41. Gianni L, Munzone E, Capri G, et al: Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines J Natl Cancer Inst 87:1169-1175, 1995.
42. Winer E, Berry D, Duggan D, et al: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 17:101, 1998.
43. Wilson W, Berg S, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994.
44. Seidman A, Hochhauser D, Gollub M, et al: Ninety-six hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 14:1877-1884, 1996.
45. Riseberg D, Cowan K, Tolcher A, et al: 96-Hour paclitaxel without and with r-verapamil in patients with metastatic breast cancer previously treated with 3- or 24-hour paclitaxel. Proc Am Soc Clin Oncol 14:180, 1995.
46. Mamounas E, Brown A, Smith R, et al: Effect of taxol duration of infusion in advanced breast cancer: results from NSABP B-26 trial comparing 3- to 24-hr infusion of high dose taxol. Proc Am Soc Clin Oncol 17:101, 1998.
47. Holmes F, Valero V, Buzdar A, et al: Final results: randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients with met breast cancer. Proc Am Soc Clin Oncol 17:110, 1998.
48. Seidman A, Murphy B, Hudis C, et al: Activity of taxol by weekly 1 hour infusion in patients with metastatic breast cancer: a phase II and pharmacologic study. Proc Am Soc Clin Oncol 16:148, 1997.
49. Asbury R, Chang A, Boros L, et al: Weekly moderate-dose paclitaxel in advanced breast cancer. Proc Am Soc Clin Oncol 17:127, 1998.
50. Sola C, Llucj A, Garcia-Conde J, et al: Phase II study of weekly paclitaxel in recurrent breast cancer after high-dose chemotherapy. Proc Am Soc Clin Oncol 17:174, 1998.
51. Sikov W, Akerley W, Strenger R, et al: Weekly high-dose paclitaxel demonstrates significant activity in advanced breast cancer. Proc Am Soc Clin Oncol 17:112, 1998.
52. Loesch D, Robert N, Keller A, et al: Phase II trial multicenter of a weekly taxol, 5-fluorouracil and leukovorin regimen in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 17:155, 1998.
53. Geyer C, Green S, Moinpour C, et al: A Phase II trial of paclitaxel in patients with metastatic refractory carcinoma of the breast: a Southwest Oncology Group (SWOG) study. Proc Am Soc Clin Oncol 15:107, 1996.
54. Sledge G, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin vs. paclitaxel vs. doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer: an intergroup trial. Proc Am Soc Clin Oncol 16:1, 1997.
55. Neuberg D, Sledge G, Fetting J, et al: Changes in quality of life during induction therapy in patients enrolled in a randomized trial of adriamycin, taxol, and adriamycin plus taxol. Proc Am Soc Clin Oncol 16:54, 1997.
56. Gamucci T, Piccart M, Bruning P, et al: Single agent taxol versus doxorubicin as first-line chemotherapy in advanced breast cancer. Final results of an EORTC randomized study with crossover. Proc Am Soc Clin Oncol 17:111. 1998.
57. Buzdar A, Morris A, Hortobagyi G, et al: Prospective randomized trial of taxol alone versus fluorouracil, doxorubicin, cyclo-phosphamide (FAC) as an induction therapy in patients with operable breast cancer. Proc Am Soc Clin Oncol 16:141, 1997.
58. Holmes F, Frye D, Valero V, et al: Phase I study of taxol and doxorubicin with G-CSF in patients without prior chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 11:60, 1992.
59. McCaskill-Stevens W, Sparano J, Cobleigh M, et al: Pilot trial of alternating paclitaxel and doxorubicin in advanced breast cancer. Breast J 3:19-24, 1997.
60. Gianni L, Straneo M, Capri G, et al: Optimal dose and sequence finding study of paclitaxel by 3-hour infusion combined with bolus doxorubicin in untreated metastatic breast cancer patients. Proc Am Soc Clin Oncol 13:74, 1994.
61. Sledge G, Robert N, Sparano J, et al: Paclitaxel (taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Experience. Semin Oncol 21(Suppl 8):15-18, 1994.
62. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995.
63. Fisherman J, Cowan K, Noone M, et al: Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol 14:774-782, 1996.
64. Holmes F, Newman R, Madden T, et al: Schedule dependent pharmacokinetics in a phase I trial of taxol and doxorubicin as initial chemotherapy for metastatic breast cancer. Ann Oncol 5:197, 1994.
65. Berg S, Cowan K, Balis F, et al: Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 86:143-145, 1994.
66. Frassineti G, Zoli W, Silvestro L, et al: Paclitaxel plus doxorubicin in breast cancer: an Italian experience. Sem Oncol 24(5 Suppl 17):S17-19-S 17-25, 1997.
67. Valagussa P, Gianni L, Capri G, et al: Three-year follow-up in women with metastatic breast cancer after bolus doxorubicin and paclitaxel infused over 3 hours. Proc Am Soc Clin Oncol 17:111, 1998.
68. Gianni L, Dombemowsky P, Sledge G, et al: Cardiac function following combination therapy with taxol and doxorubicin for advanced breast cancer. Proc Am Soc Clin Oncol 17:115, 1998.
69. Citardi M, Rowinsky E, Schaefer K, et al: Sequence-dependent cytotoxicity between cisplatin and antimicrotubule agents taxol and vincristine. Proc Am Assoc Cancer Res 31:2431, 1990.
70. Rowinsky E, Gilbert M, McGuire W, et al: Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991.
71. Gelmon K, O'Reilly S, Tolcher A, et al: Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 14:1185-1191, 1996.
72. Wasserheit C, Frazein A, Oratz R, et al: Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol 14:1993-1999, 1996.
73. McCaskill-Stevens W, Ansari R, Fisher W, et al: Phase II study of biweekly cisplatin and paclitaxel in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 15:120, 1996.
74. Sparano J, Neuberg D, Glick J, et al: A phase II trial of biweekly paclitaxel and cisplatin in patients with advanced breast carcinoma: an Eastern Cooperative Oncology (ECOG) trial (El 194). Proc Am Soc Clin Oncol 15:114, 1996.
75. Perez E, Suman V, Krook J, et al: Phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast cancer: a North Central Cancer Treatment Group trial. Proc Am Soc Clin Oncol 17:165, 1998.
76. Fountzilas G, Dimopoulos A, Bafaloukos D, et al: Paclitaxel and carboplatin as first line chemotherapy in advanced breast cancer. Proc Am Soc Clin Oncol 17:141, 1998.
77. Klassen U, Wilke H, Philippou Pari C, et al: Phase I/II study of paclitaxel in combination with weekly high dose 5-FU/folinic acid in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 14:122, 1995.
78. Klassen U, Wilke H, Muller C, et al: Infusional 5-fluorouracil/leukovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study. Sem Oncol 24(5 Suppl 17):S17-58-S 17-60, 1997.
79. Nicholson B, Paul D, Hande K: A phase II trial of paclitaxel, 5-fluorouracil and leukovorin in metastatic breast cancer. Proc Am Soc Clin Oncol 15:102, 1996.
80. Paul D, Garrett A, et al: A phase II trial of paclitaxel, 5-fluorouracil and leukovorin (TFL) in metastatic breast cancer. Proc Am Soc Clin Oncol 14:140, 1995.
81. Johnson D, Paul D, Hande K: Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. Sem Oncol 24(1 Suppl 3):S22-25, 1997.
82. Hainsworth J, Jomes S, Mennel R, et al: Paclitaxel with mitoxantrone, fluorouracil, and high-dose leukovorin in the treatment of metastatic breast cancer: a phase II trial. J Clin Oncol 14:1611-1616, 1996.
83. Pagani O, Sessa C, Goldhirsch A, et al: Taxol and cyclophosphamide in patients with advanced breast cancer: a dose-finding study with the addition of G-CSF. Proc Am Soc Clin Oncol 13:61, 1994.
84. Kennedy M, Zahurak M, Donehower R, et al: Phase I and pharmacologic study of the sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol 14:783-791, 1996.
85. Sessa C, Pagani O, Martinelli G, et al: Dose-finding study of paclitaxel and cyclophosphamide in women with advanced breast cancer. Sem Oncol 24(5 Suppl 17):S17-52-S17-57, 1997.
86. Tolcher A, Cowan K, Riley J, et al: Phase I study of paclitaxel and cyclophosphamide and G-CSF in metastatic breast cancer. Proc Am Soc Clin Oncol 13:73, 1994.
87. Murad A, Guirmaraes R, Amorim W, et al: Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. Breast Cancer Res Treat 45:47-53, 1997.
88. Weiselberg L, Budman D, O'Mara V, et al: Phase I Trial of sequential vinorelbine-paclitaxel in patients with metastatic breast cancer: early evidence of tolerability and efficacy. Proc Am Soc Clin Oncol 15:97, 1996.
89. Tortoriello A, Facchini G, Caponigro F, et al: A phase I/early phase II with vinorelbine + paclitaxel + CSFs in advanced breast cancer: preliminary data. Ann Oncol 7(Suppl 5):23, 1996.
90. Willey J, Inbrahim N, Walters R, et al: Vocal cord paralysis secondary to biweekly vinorelbine and paclitaxel by simultaneous 3-hour infusion with G-CSF support as frontline therapy for metastatic breast cancer patients. Proc Am Soc Clin Oncol 17:183, 1998.
91. Martin M, Garcia Carbonero I, Lluch A, et al: Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure. Proc Am Soc Clin Oncol 17:158, 1998.
92. Gardin G, Pronzato P, Tognoni A, et al: A phase II trial of vinorelbine and paclitaxel in patients with metastatic breast cancer who have failed prior anthracycline containing chemotherapy. Proc Am Soc Clin Oncol 17:142, 1998.
93. Ellis G, Gralow J, Pierce H, et al: Paclitaxel/vinorelbine chemotherapy with concurrent G-CSF for metastatic breast cancer: phase MI study in doxorubicin-treated patients. Proc Am Soc Clin Oncol 17:138, 1998.
94. Gianni L, Capri G, Mezzelani A, et al: Her-2/neu amplification and response to doxorubicin/paclitaxel in women with metastatic breast cancer. Proc Am Soc Clin Oncol 16:139, 1997.
95. Colomer R, Montere S, Lluch A, et al: Circulating Her-2/neu predicts resistance to taxol/adriamycin in metastatic breast carcinoma: preliminary results of a multicentric prospective study. Proc Am Soc Clin Oncol 16:140, 1997.
96. Slender M, Neuberg D, Wood W, et al: Correlation of circulating c-erb B-2 extracellular domain (Her-2) with clinical outcome in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 16:154, 1997.
97. Trudeau M, Eisenhauer E, Higgins B, et al: Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 14:422-428, 1996.
98. Hudis C, Seidman A, Crown J, et al: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14:58-65, 1996.
99. Fumoleau P, Chevallier B, Kerbrat P, et al: A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 7:165-171, 1996.
100. Chevallier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for the Research and Treatment of Cancer. J Clin Oncol 13:314-322, 1995.
101. Dieras V, Fumoleau P, Chevallier B, et al: Second EORTC Clinical Screening Group Phase II trial of taxotere (docetaxel) as first line chemotherapy in advanced breast cancer. Proc Am Soc Clin Oncol 13:78, 1994.
102. Ravdin P, Valero V, Burris H, et al: Docetaxel (taxotere) therapy in anthracycline/anthracenedione or paclitaxel resistant metastatic breast cancer. Proc Am Soc Clin Oncol 14:94, 1995.
103. Ravdin P, Burris H, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995.
104. Valero V, Holmes F, Walters R, et al: Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995.
105. van Oosterom A, Dieras V, Tubiana-Hulin M, et al: Taxotere in previously treated patients with metastatic breast carcinoma: stratification for anthracycline resistance. Proc Am Soc Clin Oncol 15:141, 1996.
106. Trandafir L, Chafine A, Spielman M, et al: Efficacy of taxotere in advanced breast cancer patients not eligible for further anthracycline. Proc Am Soc Clin Oncol 15:105, 1996.
107. Bonneterre J, Misset J, Guastalla J, et al: Feasibility and safety of taxotere in heavily pretreated metastatic breast cancer: preliminary report of a Multicentric Compassionate Use Program. Proc Am Soc Clin Oncol 15:116, 1996.
108. Leonard R, O'Brien M, Barrett-Lee P, et al: A prospective analysis of 390 advanced breast cancer patients treated with taxotere throughout the UK. Ann Oncol 7(Suppl 5):19, 1996.
109. Löffler T, Dreund W, Droge C, et al: Activity of weekly taxotere in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 17:113, 1998.
110. Valero V, Burris H, Jones S, et al: Multicenter pilot study of taxotere in taxol-resistant metastatic breast cancer. Proc Am Soc Clin Oncol 15:107, 1996.
111. Bourgeois H, Gruia G, Dieras V, et al: Docetaxel in combination with doxorubicin as first line chemotherapy of metastatic breast cancer: a phase I dose finding study. Proc Am Soc Clin Oncol 15:148, 1996.
112. Misset J, Dieras V, Bozec L, et al: Long term follow up of the phase I/II study of docetaxel and doxorubicin as 1st line chemotherapy of metastatic breast cancer. Proc Am Soc Clin Oncol 17:160, 1998.
113. Kerbrat P, Viens P, Roche H, et al: Doxetaxel in combination with epirubicin as 1st line chemotherapy of metastatic breast cancer: final results. Proc Am Soc Clin Oncol 17:151, 1998.
114. Alexopoulos A, Kouroussis C, Kakolyris S, et al: A phase I/II study of docetaxel and mitoxantrone in metastatic breast cancer. Proc Am Soc Clin Oncol 17:126, 1998.
115. Bernard A, Antoine A, Gozy M, et al: Docetaxel and cisplatin in anthracycline-pretreated advanced breast cancer: results of a phase II pilot study. Proc Am Soc Clin Oncol 17:128, 1998.
116. Llombart-Cussac A, Spielmann M, Dohollou N, et al: cis-Platinum-taxotere phase I/II trial in patients with anthracycline-resistant advanced breast cancer. Proc Am Soc Clin Oncol 16:180, 1997.
117. Watanabe T, Adachi I, Sasaki Y, et al: A phase I/II study of docetaxel in combination with 5-fluorouracil for advanced or recurrent breast cancer. Ann Oncol 7 (Suppl 5):21, 1996.
118. Rowinsky E, Smith L, Rodriguez G, et al: Docetaxel in combination with fluorouracil: study design and preliminary results. Sem Oncol 11(6 Suppl 6):S33-35, 1997.
119. Fumoleau P, Delecroix V, Perrocheau G, et al: Docetaxel in combination with vinorelbine as first line chemotherapy in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 15:142, 1996.
120. Escudero P, Bueso P, Mayordome J, et al: Docetaxel + vinorelbine is an active combination for patients with anthracyclin-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 17:139, 1998.
121. Valero V: Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. Oncology 11(8 Suppl 8):34-36, 1997.
122. Mavroudis D, Kouroussis C, Malamos N, et al: A phase II trial of docetaxel and gemcitabine as second line treatment in metastatic breast cancer. Proc Am Soc Clin Oncol 17:158, 1998.
123. Crown J: Summary of results of a randomized phase III trial of docetaxel versus doxorubicin in patients with metastatic breast cancer and prior alkylating agent exposure, 20th Annual San Antonio Breast Cancer Conference. San Antonio, TX, Physicians' Education Resource, 1997, pp 2-3.
124. Nabholtz J, Thuerlimann B, Bezwoda W, et al: Docetaxel vs. Mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. Oncology 11(8 Suppl 8):25-30, 1997.
125. Sjöström J, Mouridsen H, Pluzanska A, et al: Taxotere versus methotrexate-5-fluorouracil in patients with advanced anthracycline resistant breast cancer: preliminary results of a randomized phase III study by Scandinavian Breast Cancer Group. Proc Am Soc Clin Oncol 17:111, 1998.
126. Bonneterre J, Roche H, Monnier A, et al: Taxotere versus 5-fluorouracil + navelbine as second-line chemotherapy in patients with metastatic breast cancer (preliminary results). Proc Am Soc Clin Oncol 16:162, 1997.
127. Botto H, Botto M, Otegui M, et al: Taxotere vs. vinorelbine and taxol in patients with metastatic breast cancer anthracycline resistance. Proc Am Soc Clin Oncol 17:130, 1998.
128. Demetri G, Berry D, Younger J, et al: Dose-intensified cyclophosphamide/doxorubicin followed by taxol as adjuvant systemic chemotherapy for node-positive breast cancer (CALBG 9141): randomized comparison of two dose levels of G-CSF. Proc Am Soc Clin Oncol 13:65, 1994.
129. Henderson I, Berry D, Demetri G, et al: Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am Soc Clin Oncol 17:101, 1998.
130. Hudis C, Seidman A, Raptis G, et al: Sequential doxorubicin, paclitaxel, and cyclophosphamide in women with resected breast cancer and ≥4 (+) lymph nodes: preliminary results. Proc Am Soc Clin Oncol 14:113, 1995.
131. Abrams J, Vens D, Baltz V, et al: Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute treatment referral center trial. J Clin Oncol 13:2056-2065, 1995.
132. Vermoken J, Huizing M, Liefting A, et al: High-dose taxol with G-CSF in patients with advanced breast cancer refractory to anthracycline therapy. Eur J Cancer 29A:S83, 1993.
133. Munzone E, Capri G, Demicheli R, et al: Activity of taxol by 3 hour infusion in breast cancer patients with clinical resistance to anthracyclines. Eur J Cancer 29A:S79, 1993.
134. Fountzilas G, Athanassiades A, Giannakakis T, et al: A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 32A:47-51, 1996.
135. Gehl J, Boesgaard M, Paaske T, et al: Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 7:687-693, 1996.
136. Cazap E, Ventriglia M, Rubio G, et al: Taxol plus doxorubicin treatment of metastatic breast cancer in ambulatory patients. Proc Am Soc Clin Oncol 15:146, 1996.
137. Schwartsmann G, Menke C, Caleffi M, et al: Phase II trial of taxol, doxorubicin plus G-CSF in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 15:126, 1996.
138. Martin M, Lluch A, Ojeda B, et al: Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity. Sem Oncol 24(5 Suppl 17):S17-26-S 17-30, 1997.
139. Dombernowsky P, Boesgaard M, Andersen E, et al: Doxorubicin plus paclitaxel in advanced breast cancer. Sem Oncol 24(5 Suppl 17):S17-15-S17-8, 1997.
140. Moliterni A, Tarenzi E, Capri G, et al: Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Sem Oncol 24(5 Suppl 17):S17-10-S17-14, 1997.
141. Baldini E, Innocenti F, Michelotti A, et al: Paclitaxel by 3-hour infusion plus bolus epirubicin: a feasibility and pharmacokinetic study in metastatic breast cancer. Ann Oncol 7(Suppl 5):21, 1996.
142. Luck H, Thomssen C, du Bois A, et al: Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer. Sem Oncol 24(5 Suppl 17):S17-35-S17-39, 1997.
143. Conte P, Michelotti A, Baldini E, et al: Epirubicin plus paclitaxel, a highly active combination devoid of significant cardiotoxicity in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 15:118, 1996.
144. Capri G, Tarenzi E, Bertuzzi A, et al: Paclitaxel by 3-hour infusion and bolus epirubicin on day 1 & 8 every three-weeks in women with metastatic breast cancer. Ann Oncol 7(Suppl 5):16-22, 1996.
145. Ries F, Duhem C, Kleiber K, et al: Phase I/II clinical trial of epirubitin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer. Sem Oncol 24(5 Suppl 17):S 17-48-S17-51, 1997.
146. Carmichael J, Jones A, Hutchinson T: A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. United Kingdom coordinating committee for cancer research breast cancer subcommittee. Sem Oncol 24(5 Suppl 17):S17-44-S17-47, 1997.
147. Alabiso O, Durando A, Malossi A, et al: Paclitaxel and epidoxo-rubicin regimen as first-line therapy in metastatic breast cancer. A phase I-II study. Proc Am Soc Clin Oncol 17:125, 1998.
148. Köhler U, Olbricht S, Fuechsel G, et al: Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer; results of a clinical phase II study. Sem Oncol 24(5 Suppl 17):S17-40-S17-43, 1997.
149. DiCostanzo F, Sdrobolini A, Bilancia D, et al: Phase I-II trial of mitoxantrone and taxol in advanced breast cancer. Proc Am Soc Clin Oncol 15:139, 1996.
150. Panagos G: Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group. Sem Oncol 24(1 Suppl 3):S17-21, 1997.
151. Greco F, Hainsworth J: Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leukovorin in the treatment of metastatic breast cancer. Sem Oncol 24(5 Suppl 17):S 17-61-S17-64, 1997.
152. Ten Bokkel Huinink W, van Oosterom A, Piccart M, et al: Taxotere in advanced breast cancer: a phase II trial of the EORTC Early Clinical Trials group. Proc Am Soc Clin Oncol 12:70, 1993.
153. Adachi I, Watanabe T, Takashima S, et al: A phase II study of RP56976 (docetaxel) in patients with advanced or recurrent metastatic breast cancer. Br J Cancer 73:210-216, 1996.
154. Guastalla J, Bonneterre J, Fumoleau P, et al: A phase II trial of docetaxel in patients with anthracycline resistant metastatic breast cancer. Eur J Cancer 31A(Suppl 5):S75-76, 1995.
155. Nabholtz J-M: Docetaxel, doxorubicin and cyclophosphamide in the treatment of metastatic breast cancer, 20th Annual San Antonio Breast Cancer Conference. San Antonio, TX, Physicians' Education Resource, 1997, pp 7-9.
156. Bishop J, Dewar J, Tattersall M, et al: A randomized phase III study of taxol (paclitaxel) vs. CMFP. in untreated patients with metastatic breast cancer. Proc Am Soc Clin Oncol 15:110, 1996.